Crossmark

ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aβ Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan

Crossref DOI link: https://doi.org/10.14283/jpad.2022.93

Published Print: 2023-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Siemers, Eric

Hitchcock, J.

Sundell, K.

Dean, R.

Jerecic, J.

Cline, E.

Iverson, K.

Moore, J.

Edgar, C.

Manber, R.

Fuin, N.

Poppe, T.

Barton, R.
License Information

Text and Data Mining valid from 2023-01-01

Text and Data Mining valid from 2023-01-01

Version of Record valid from 2022-10-26
More Information

This article is maintained by: Elsevier

Article Title: ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aβ Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan

Journal Title: The Journal of Prevention of Alzheimer's Disease

CrossRef DOI link to publisher maintained version: https://doi.org/10.14283/jpad.2022.93

Content Type: article

Copyright: Copyright © 2022 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS